JP2002500180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500180A5 JP2002500180A5 JP2000527235A JP2000527235A JP2002500180A5 JP 2002500180 A5 JP2002500180 A5 JP 2002500180A5 JP 2000527235 A JP2000527235 A JP 2000527235A JP 2000527235 A JP2000527235 A JP 2000527235A JP 2002500180 A5 JP2002500180 A5 JP 2002500180A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- disulfiram
- medical device
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 30
- 239000008194 pharmaceutical composition Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 16
- 229960002563 disulfiram Drugs 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 12
- 230000033115 angiogenesis Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 230000000926 neurological effect Effects 0.000 description 6
- 208000023178 Musculoskeletal disease Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010018691 Granuloma Diseases 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 3
- 208000009292 Hemophilia A Diseases 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 230000005744 arteriovenous malformation Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000867 larynx Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 201000003142 neovascular glaucoma Diseases 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001698 pyrogenic effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 206010044325 trachoma Diseases 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 208000009129 Ear Neoplasms Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000026037 malignant tumor of neck Diseases 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL122892 | 1998-01-11 | ||
| IL12289298A IL122892A0 (en) | 1998-01-11 | 1998-01-11 | Pharmaceutical compositions comprising a thiocarbamate |
| PCT/IL1999/000017 WO1999034784A2 (en) | 1998-01-11 | 1999-01-11 | Pharmaceutical compositions comprising disulfiram for inhibiting angiogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500180A JP2002500180A (ja) | 2002-01-08 |
| JP2002500180A5 true JP2002500180A5 (enExample) | 2006-02-23 |
Family
ID=11071076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527235A Pending JP2002500180A (ja) | 1998-01-11 | 1999-01-11 | ジスルフィラムで構成される医薬品組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6288110B1 (enExample) |
| EP (1) | EP1047416B1 (enExample) |
| JP (1) | JP2002500180A (enExample) |
| AT (1) | ATE401879T1 (enExample) |
| AU (1) | AU1888599A (enExample) |
| DE (1) | DE69939155D1 (enExample) |
| DK (1) | DK1047416T3 (enExample) |
| IL (1) | IL122892A0 (enExample) |
| WO (1) | WO1999034784A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6589987B2 (en) | 1998-09-08 | 2003-07-08 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using tetraethyl thiuram disulfide |
| US6706759B1 (en) | 1998-09-08 | 2004-03-16 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US6548540B2 (en) * | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US7816403B2 (en) * | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
| AU2002226650A1 (en) * | 2001-01-18 | 2002-07-30 | Arnold Hoffman | Redox therapy for tumors |
| US20040157837A1 (en) * | 2002-11-07 | 2004-08-12 | Serbedzija George N. | Combinations for the treatment of fungal infections |
| WO2007065167A1 (en) * | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
| WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| WO2008068746A2 (en) * | 2006-12-04 | 2008-06-12 | Yeda Research And Development Co. Ltd. | Disulfiram doses and treatment regimen suitable for treatment of angiogenesis-dependent disorders |
| US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
| WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
| EP2632450A1 (en) * | 2010-08-31 | 2013-09-04 | Avidal Vascular GmbH | Compositions comprising a taxane for coating medical devices |
| JP6206939B2 (ja) * | 2011-10-11 | 2017-10-04 | 国立大学法人 千葉大学 | 肝がん幹細胞阻害剤 |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| WO2015120254A1 (en) * | 2014-02-06 | 2015-08-13 | Texas Tech University System | Disulfiram compositions and treatments for brain tumors |
| GB201407806D0 (en) | 2014-05-02 | 2014-06-18 | Ucl Business Plc | Treatment of fibrosis |
| GB201519643D0 (en) * | 2015-11-06 | 2015-12-23 | Univ Wolverhampton | Disulfiram formulation |
| WO2017177947A1 (zh) | 2016-04-13 | 2017-10-19 | 诺马（北京）科技有限公司 | 局部注射双硫仑制剂治疗胸腹膜癌症的方法 |
| EP3311843A1 (en) | 2016-10-13 | 2018-04-25 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Compositions comprising dithiocarbamate and cyclodextrin |
| US11298396B2 (en) | 2017-03-17 | 2022-04-12 | Osaka University | Agent for inhibiting or reducing light sensitivity |
| EP3813805A4 (en) * | 2018-06-27 | 2021-08-25 | Children's Medical Center Corporation | INFLAMMATION INHIBITION COMPOUNDS |
| US11311538B2 (en) | 2018-07-13 | 2022-04-26 | Yale University | Compositions and methods for targeting cancers |
| EP3693740A1 (en) | 2019-02-07 | 2020-08-12 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Improved dithiocarmabate based compounds, therapies and diagnostics |
| KR20210049403A (ko) * | 2019-10-25 | 2021-05-06 | 연세대학교 산학협력단 | 암의 예방 또는 치료용 조성물 |
| EP4135660A1 (en) * | 2020-04-16 | 2023-02-22 | Atossa Therapeutics, Inc. | Compositions and methods to reduce the infectivity of a virus |
| WO2021231814A1 (en) * | 2020-05-14 | 2021-11-18 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for the treatment and prevention of vascular malformations |
| US12070468B2 (en) * | 2020-05-14 | 2024-08-27 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for the treatment and prevention of vascular malformations |
| WO2022061171A1 (en) * | 2020-09-18 | 2022-03-24 | Spring Discovery, Inc. | Combination therapies with disulfiram |
| US11065214B1 (en) * | 2020-09-18 | 2021-07-20 | Spring Discovery, Inc. | Combination therapies with disulfiram |
| CN114376997B (zh) * | 2021-10-10 | 2023-04-28 | 深圳市人民医院 | 一种新型IRE1a抑制剂紫草素及与双硫仑协同抗肿瘤组合方式 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0284879A3 (en) * | 1987-03-17 | 1990-10-17 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release |
| US4870101A (en) * | 1987-03-17 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | Method of inhibiting interleukin-1 release |
| US5807884A (en) | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
-
1998
- 1998-01-11 IL IL12289298A patent/IL122892A0/xx unknown
-
1999
- 1999-01-11 US US09/582,995 patent/US6288110B1/en not_active Expired - Lifetime
- 1999-01-11 EP EP99900280A patent/EP1047416B1/en not_active Expired - Lifetime
- 1999-01-11 DK DK99900280T patent/DK1047416T3/da active
- 1999-01-11 WO PCT/IL1999/000017 patent/WO1999034784A2/en not_active Ceased
- 1999-01-11 JP JP2000527235A patent/JP2002500180A/ja active Pending
- 1999-01-11 AT AT99900280T patent/ATE401879T1/de not_active IP Right Cessation
- 1999-01-11 DE DE69939155T patent/DE69939155D1/de not_active Expired - Lifetime
- 1999-01-11 AU AU18885/99A patent/AU1888599A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gajraj et al. | Eutectic mixture of local anesthetics (EMLA®) cream | |
| US6461644B1 (en) | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods | |
| CA2595132C (en) | Agents for controlling biological fluids and methods of use thereof | |
| US20070059350A1 (en) | Agents for controlling biological fluids and methods of use thereof | |
| US5589480A (en) | Topical application of opioid analgesic drugs such as morphine | |
| US5272139A (en) | Amelioration or elimination of postoperative pain | |
| JP2003512401A (ja) | 外科的に閉じた創傷部からの疼痛の局所的抑制または改善 | |
| JP2011507665A (ja) | 粘膜組織包帯剤及び使用方法 | |
| KR101900520B1 (ko) | 복합 조성물 | |
| BR0108730A (pt) | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados | |
| JP2001510795A5 (enExample) | ||
| SK11193A3 (en) | Formulations containing hyaluronic acid | |
| US8535709B2 (en) | Agents for controlling biological fluids and methods of use thereof | |
| CZ9300229A3 (cs) | Kombinační prostředky pro léčení bazocelulárního karcinomu nebo aktinických keratóz | |
| PL376217A1 (en) | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics | |
| US8790688B2 (en) | Wound care device for local treatment of pain in a wound | |
| EP3359221B1 (en) | Drug delivery system and method for controlled and continuous delivery of drugs into the brain by bypassing the blood brain barrier | |
| Shin et al. | Dental treatment in patients with severe gag reflex using propofol-remifentanil intravenous sedation | |
| EP1121929A4 (en) | "HISTOCHROME" PRODUCT PREPARATION FOR THE TREATMENT OF EYE DISEASES | |
| JP5796728B1 (ja) | 創傷治癒を促進し生体諸臓器の被覆（コーチング）及び庇護を目的とした生体皮膜剤。 | |
| US4017619A (en) | Anesthetic and sedative composition | |
| Shafik | Treatment of tuberculous epididymitis by intratunical rifampicin injection | |
| JP3782551B2 (ja) | 鎮痛組成物 | |
| WO2019008472A1 (en) | PHARMACEUTICAL COMPOSITIONS OF LIGNOCAINE HCL | |
| EP1347753B1 (en) | Topical composition and method for treating urinary stress incontinence |